Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients

@article{Verschueren2007DevelopmentOS,
  title={Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients},
  author={K. Verschueren and E. V. Essche and P. Verschueren and V. Taelman and R. Westhovens},
  journal={Clinical Rheumatology},
  year={2007},
  volume={26},
  pages={1969-1971}
}
We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by etanercept. Both women, aged 46 and 53, had erosive, rheumatoid-factor-positive rheumatoid arthritis (RA) for 7 and 6 years, respectively. The eldest had received infliximab for over a year with good response, which was stopped because of a perfusion reaction. She developed a cough and dyspnea after 6 months of etanercept treatment. The other developed erythema nodosum and a plaque lesion on the right arm… Expand
Development of sarcoidosis during etanercept therapy.
TLDR
A 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis was discontinued, which resulted in symptomatic relief, improvement of oxygenation and radiologic findings. Expand
Abrupt Development of Sarcoidosis with a Prodromal Increase in Plasma Osteopontin in a Patient with Rheumatoid Arthritis During Treatment with Etanercept
TLDR
A 52-year-old Japanese woman with rheumatoid arthritis had acute onset of sarcoidosis in several organs simultaneously after a long period of remission of RA while receiving etanercept, and might have developed as quickly as within 1 or 2 months. Expand
Developing of granulomatous thyroiditis during etanercept therapy
TLDR
A 32-year-old man who developed granulomatous thyroiditis (GT) during etanercept therapy for rheumatoid arthritis (RA) is described and is asymptomatic with rituximab, methotrexate, and levothyroxine therapy. Expand
Relapse of sarcoidosis upon treatment with etanercept
TLDR
A 35-year-old woman with a history of sarcoidosis, in remission while on no treatment, and ankylosing spondylitis experienced a severe flare of inflammatory back pain that was not responsive to non-steroidal anti-inflammatory drugs. Expand
Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
TLDR
2 patients with inflammatory rheumatic disease, the first with ankylosing spondylitis, the second with rheumatoid arthritis, under anti-TNF-alpha treatment (infliximab and etanercept respectively) who developed non-caseating granulomas of the lungs and lymph nodes consistent with the diagnosis of sarcoidosis are described. Expand
Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature
TLDR
This case is, to the authors' knowledge, the first to describe adalimumab-induced non-caseating granulomas in lymph nodes and bone marrow without pulmonary involvement in a patient treated for rheumatoid arthritis. Expand
Development of sarcoidosis following etanercept treatment: a report of three cases
TLDR
This paper presents three patients who developed sarcoidosis while on etanercept treatment, and discusses if possible differences in cytokine profiles and T regulatory cell function in patients taking different TNF-α inhibitors may explain this paradox. Expand
Acute Sarcoidosis (Löfgren's Syndrome) in a Patient Treated with Etanercept for Psoriatic Arthritis-Case Report and Impacts of Biologic Agents Review
TLDR
This study aims to present the case of a female patient treated with etanercept for severe psoriasis arthritis (PsA) who subsequently developed acute sarcoidosis and to examine the risk of serious adverse events. Expand
A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature
TLDR
A 33-year-old woman with a history of juvenile rheumatoid arthritis and refractory uveitis who had been stable for 2 years on etanercept is described, which demonstrates the difficulty of choosing tumour necrosis factor α (TNF-α) inhibitors when treating patients with multiple clinical autoimmune entities. Expand
Lung Sarcoidosis in Etanercept Treated Rheumatoid Arthritis Patient: A Case Report and Review of the Literature
TLDR
A 55-year-old female with seropositive rheumatoid arthritis for 10 years who developed large mediastinal and hilar adenopathy while receiving etanercept therapy is reported to increase awareness of pulmonary sarcoidosis development in patient treated with tumor necrosis factor-alpha blocking agent, etanerscept. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Treatment of sarcoidosis with infliximab.
TLDR
Infliximab appears to be an effective, safe treatment for patients with refractory sarcoidosis, including such manifestations as lupus pernio, uveitis, hepatic sarcoidsosis, and neurosarcoidotic disorders. Expand
A possible association of rheumatoid arthritis and sarcoidosis.
TLDR
It is demonstrated that two patients with rheumatoid arthritis may present with stage III sarcoidosis, and the prevalence in this clinic population is two per 263 as compared with 20 to 80 per 100,000 in the general population. Expand
Pulmonary sarcoidosis
TLDR
Alternative and corticosteroid‐sparing therapies are of increased interest in difficult cases, while targeted new drugs such as anti‐TNF‐α are still under investigation. Expand
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.
TLDR
In patients with progressive stage II or III pulmonary sarcoidosis, etanercept was frequently associated with early or late treatment failure, and data would not support the design of a large multicenter randomized trial comparing etanenercept with conventional corticosteroid therapy. Expand
The utility of tumour necrosis factor blockade in orphan diseases
  • E. Keystone
  • Medicine
  • Annals of the rheumatic diseases
  • 2004
TLDR
Results lend further support for the concept of differential mechanism(s) of action of the two antagonists with infliximab being more effective for the treatment of granulomatous diseases. Expand
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
TLDR
There are significant differences between the 2 classes of TNF antagonists in terms of both their kinetics and mechanisms of action, which may help explain the apparent differences in the incidence of granuloma-dependent infections among them. Expand
Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.
TLDR
Evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed. Expand
Differentiating the efficacy of the tumor necrosis factor inhibitors.
  • B. Haraoui
  • Medicine
  • Seminars in arthritis and rheumatism
  • 2005
TLDR
The purpose of this brief review is to summarize current efficacy data and explore possible explanations for observed clinical differences in rheumatoid arthritis. Expand
The cytokine network in sarcoidosis and its clinical relevance
TLDR
The cytokine network in sarcoidosis and its clinical relevance is studied in detail at the Minisymposium of the University Hospital Freiburg. Expand
Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
  • C. Dinarello
  • Medicine
  • The Journal of rheumatology. Supplement
  • 2005
This review examines the differences in the incidence, spectrum, and mechanisms of activation of opportunistic infections, such as Mycobacterium tuberculosis, in patients with rheumatic diseasesExpand
...
1
2
...